(Bloomberg) — Chinese biotech company Beigene Ltd. plans to raise $2.1 billion in a direct offering of 145.8 million shares to fund drug research and market its treatments in the U.S. and China, said the Nasdaq-listed company on Monday.The shares will be priced at $14.23 each, equivalent to a price of $185 per American Depository Share — 5.6% lower than its closing price on Friday. The offering is expected to close on or around July 15, said the company, whose shares are also traded in Hong Kong.Buyers in the share sale include investment firm Baker Bros. Advisors LP and American …read more
Source:: Yahoo Finance
